At GSK, our Ellipta portfolio delivers an effective and simple approach to COPD treatment, whilst our Ellipta device is the only once-daily inhaler that enables device continuity for patients with COPD.
As well as our Ellipta portfolio of COPD treatments, we are also committed to improving patient outcomes through the resources we offer. Our Ellipta demonstration device can help you demonstrate correct use of the Ellipta inhaler to your patients.
IMPORTANT: The Ellipta demonstration device is intended for demonstration only and not for patient use. Patients should not inhale from the demonstration device.
- Trelegy SmPC 2022, available at www.medicines.ie
- Anoro Ellipta SmPC 2022, available at www.medicines.ie
- Incruse SmPC 2022, available on www.medicines.ie
- van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079
Developed in association with INNOVIVA.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1 80 0 2 442 5 5.
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.
© 2021 GlaxoSmithKline Group of Companies. Anoro, Incruse, Relvar, Trelegy and Ellipta are trademarks of the GSK group of companies.